Generic OraVerse Availability
OraVerse is a brand name of phentolamine, approved by the FDA in the following formulation(s):
ORAVERSE (phentolamine mesylate - injectable;injection)
-
Manufacturer: SEPTODONT HOLDING
Approval date: May 9, 2008
Strength(s): 0.4MG/1.7ML [RLD]
Has a generic version of OraVerse been approved?
No. There is currently no therapeutically equivalent version of OraVerse available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of OraVerse. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Local anesthetic methods and kits
Patent 6,764,678
Issued: July 20, 2004
Inventor(s): Eckard; Weber & Howard I.; Katz
Assignee(s): Novalar Pharmaceuticals, Inc.
Methods of reversing local anesthesia are disclosed. The methods comprise administering a local anesthetic and alpha adrenergic receptor agonist to induce local anesthesia followed by reversing anesthesia with a low dose of an alpha adrenergic receptor antagonist. Also disclosed are kits comprising a local anesthetic, an alpha adrenergic receptor agonist and a low dose of an alpha adrenergic receptor antagonist.Patent expiration dates:- May 11, 2021✓
- May 11, 2021
-
Local anesthetic methods and kits
Patent 6,872,390
Issued: March 29, 2005
Inventor(s): Weber; Eckard & Katz; Howard I.
Assignee(s): Novalar Pharmaceuticals, Inc.
Methods of reversing local anesthesia are disclosed. The methods comprise administering a local anesthetic and alpha adrenergic receptor agonist to induce local anesthesia followed by reversing anesthesia with a low dose of an alpha adrenergic receptor antagonist. Also disclosed are kits comprising a local anesthetic, an alpha adrenergic receptor agonist and a low dose of an alpha adrenergic receptor antagonist.Patent expiration dates:- May 11, 2021✓
- May 11, 2021
-
Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
Patent 7,229,630
Issued: June 12, 2007
Inventor(s): Chen; Andrew X. & Knowles; Julius & Weber; Eckard
Assignee(s): Novalar Pharmaceuticals, Inc.
The present invention provides compositions and stable liquid formulations comprising alpha adrenergic receptor antagonists and use thereof for increasing blood flow. In one embodiment, the stable liquid formulations of this invention are useful for reversing the effects of an anesthetic agent, preferably a long-lasting local anesthetic agent administered in conjunction with an alpha adrenergic receptor agonist.Patent expiration dates:- June 20, 2023✓
- June 20, 2023
-
Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
Patent 7,569,230
Issued: August 4, 2009
Inventor(s): Chen; Andrew X & Knowles; Julius & Weber; Eckard
Assignee(s): Novalar Pharmaceuticals, Inc.
The present invention provides compositions and stable liquid formulations comprising alpha adrenergic receptor antagonists and use thereof for increasing blood flow. In one embodiment, the stable liquid formulations of this invention are useful for reversing the effects of an anesthetic agent, preferably a long-lasting local anesthetic agent administered in conjunction with an alpha adrenergic receptor agonist.Patent expiration dates:- October 17, 2023✓
- October 17, 2023
-
Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
Patent 7,575,757
Issued: August 18, 2009
Inventor(s): Chen; Andrew X. & Knowles; Julius & Weber; Eckard
Assignee(s): Novalar Pharmaceuticals, Inc.
The present invention provides compositions and stable liquid formulations comprising alpha adrenergic receptor antagonists and use thereof for increasing blood flow. In one embodiment, the stable liquid formulations of this invention are useful for reversing the effects of an anesthetic agent, preferably a long-lasting local anesthetic agent administered in conjunction with an alpha adrenergic receptor agonist.Patent expiration dates:- April 21, 2025✓
- April 21, 2025
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- March 18, 2019 - NEW PATIENT POPULATION
More about OraVerse (phentolamine)
Consumer resources
- Other brands: Regitine
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
